lactic acid has been researched along with Uveitis in 10 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Uveitis: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The therapeutic effects of betamethasone phosphate (BP) encapsulated in biocompatible and biodegradable blended nanoparticles of poly(lactic acid) (PLA) homopolymers and PEG-block-PLA copolymers (stealth nanosteroids) were examined in an experimental autoimmune uveoretinitis (EAU) model in Lewis rats." | 7.77 | Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. ( Akiyama, G; Higaki, M; Ishihara, T; Sakai, T; Tsuneoka, H, 2011) |
| " In this study, we evaluated the effects of intravenously administered poly(lactic acid) nanoparticles encapsulating betamethasone phosphate (BP-PLA NPs) on experimental autoimmune uveoretinitis (EAU) in Lewis rats." | 7.73 | Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. ( Higaki, M; Ishihara, T; Kitahara, K; Kohno, H; Matsushima, M; Mizushima, Y; Saito, S; Sakai, T, 2006) |
| " It was demonstrated that the intravitreal injection of the optimized CsA-PLGA-MS decreased significantly the severity of the inflammatory signs, cellular infiltrate, aqueous leukocyte counts, and protein levels in the eyes of experimental rabbits with uveitis, compared to other formulations." | 7.73 | Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. ( He, Y; Liu, YL; Ma, ZZ; Wang, JC; Zhang, Q; Zhu, XA, 2006) |
| "Conventional treatments of uveitis are not ideal because of the short period of therapeutic efficacy." | 5.40 | Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis. ( Dai, W; He, B; Li, W; Liu, Y; Zhang, Q, 2014) |
| " The 3H-CyS-PLGA-MS suspension was injected into the vitreous body of healthy rabbits, and the concentration of cyclosporine in various ocular tissues and blood at predetermined intervals was measured by a scintillation counting technique and the pharmacokinetic parameters were calculated." | 5.33 | Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. ( He, Y; Liu, Y; Lu, W; Ma, Z; Wang, J; Zhang, Q; Zhang, X; Zhu, X, 2006) |
| "The therapeutic effects of betamethasone phosphate (BP) encapsulated in biocompatible and biodegradable blended nanoparticles of poly(lactic acid) (PLA) homopolymers and PEG-block-PLA copolymers (stealth nanosteroids) were examined in an experimental autoimmune uveoretinitis (EAU) model in Lewis rats." | 3.77 | Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. ( Akiyama, G; Higaki, M; Ishihara, T; Sakai, T; Tsuneoka, H, 2011) |
| " In this study, we evaluated the effects of intravenously administered poly(lactic acid) nanoparticles encapsulating betamethasone phosphate (BP-PLA NPs) on experimental autoimmune uveoretinitis (EAU) in Lewis rats." | 3.73 | Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. ( Higaki, M; Ishihara, T; Kitahara, K; Kohno, H; Matsushima, M; Mizushima, Y; Saito, S; Sakai, T, 2006) |
| " It was demonstrated that the intravitreal injection of the optimized CsA-PLGA-MS decreased significantly the severity of the inflammatory signs, cellular infiltrate, aqueous leukocyte counts, and protein levels in the eyes of experimental rabbits with uveitis, compared to other formulations." | 3.73 | Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. ( He, Y; Liu, YL; Ma, ZZ; Wang, JC; Zhang, Q; Zhu, XA, 2006) |
| "Uveitis is a group of ocular inflammatory disorders that can lead to severe vision loss." | 2.52 | Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. ( Robinson, MR; Whitcup, SM, 2015) |
| "Conventional treatments of uveitis are not ideal because of the short period of therapeutic efficacy." | 1.40 | Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis. ( Dai, W; He, B; Li, W; Liu, Y; Zhang, Q, 2014) |
| " Ophthalmic examination revealed no evidence of toxic effects of implants." | 1.40 | Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity. ( Da Silva, GR; Fialho, SL; Fulgêncio, GO; Silva-Cunha, A; Souza, MC; Souza, PA, 2014) |
| " The 3H-CyS-PLGA-MS suspension was injected into the vitreous body of healthy rabbits, and the concentration of cyclosporine in various ocular tissues and blood at predetermined intervals was measured by a scintillation counting technique and the pharmacokinetic parameters were calculated." | 1.33 | Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. ( He, Y; Liu, Y; Lu, W; Ma, Z; Wang, J; Zhang, Q; Zhang, X; Zhu, X, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stein, S | 1 |
| Auel, T | 1 |
| Kempin, W | 1 |
| Bogdahn, M | 1 |
| Weitschies, W | 1 |
| Seidlitz, A | 1 |
| Li, W | 1 |
| He, B | 1 |
| Dai, W | 1 |
| Zhang, Q | 3 |
| Liu, Y | 3 |
| Souza, MC | 1 |
| Fialho, SL | 1 |
| Souza, PA | 1 |
| Fulgêncio, GO | 1 |
| Da Silva, GR | 1 |
| Silva-Cunha, A | 1 |
| Whitcup, SM | 1 |
| Robinson, MR | 1 |
| Sakai, T | 2 |
| Ishihara, T | 2 |
| Higaki, M | 2 |
| Akiyama, G | 1 |
| Tsuneoka, H | 1 |
| Eperon, S | 1 |
| Rodriguez-Aller, M | 1 |
| Balaskas, K | 1 |
| Gurny, R | 1 |
| Guex-Crosier, Y | 1 |
| Sakurai, E | 1 |
| Nozaki, M | 1 |
| Okabe, K | 1 |
| Kunou, N | 1 |
| Kimura, H | 1 |
| Ogura, Y | 1 |
| Kohno, H | 1 |
| Saito, S | 1 |
| Matsushima, M | 1 |
| Mizushima, Y | 1 |
| Kitahara, K | 1 |
| He, Y | 2 |
| Wang, JC | 1 |
| Liu, YL | 1 |
| Ma, ZZ | 1 |
| Zhu, XA | 1 |
| Wang, J | 1 |
| Zhang, X | 1 |
| Lu, W | 1 |
| Ma, Z | 1 |
| Zhu, X | 1 |
1 review available for lactic acid and Uveitis
| Article | Year |
|---|---|
Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis.
Topics: Dexamethasone; Drug Delivery Systems; Humans; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polygl | 2015 |
9 other studies available for lactic acid and Uveitis
| Article | Year |
|---|---|
Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone.
Topics: Acrylic Resins; Delayed-Action Preparations; Dexamethasone; Drug Delivery Systems; Drug Implants; Dr | 2018 |
Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Carriers; Glyc | 2014 |
Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity.
Topics: Animals; Biocompatible Materials; Choroid; Drug Delivery Systems; Feasibility Studies; Female; Immun | 2014 |
Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis.
Topics: Animals; Autoimmune Diseases; Betamethasone; Biocompatible Materials; Biological Availability; Delay | 2011 |
A new drug delivery system inhibits uveitis in an animal model after cataract surgery.
Topics: Animals; Anti-Inflammatory Agents; Biocompatible Materials; Cataract Extraction; Cyclosporine; Disea | 2013 |
Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis.
Topics: Absorbable Implants; Animals; Antigens, Bacterial; Aqueous Humor; Biocompatible Materials; Cell Coun | 2003 |
Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Betamethasone; Choroid; Delayed-Action Prepa | 2006 |
Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits.
Topics: Animals; Aqueous Humor; Biocompatible Materials; Cyclosporine; Disease Models, Animal; Drug Carriers | 2006 |
Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study.
Topics: Animals; Biocompatible Materials; Chromatography, High Pressure Liquid; Cyclosporine; Drug Carriers; | 2006 |